Peter Schmid, Professor of Cancer Medicine and Clinical Director of the St. Bartholomew Breast Cancer Centre, UK, explores how risk stratification is performed in clinical practice and how treatment strategies are decided for patients with hormone-receptor positive breast cancer.
Q1. How is risk stratification performed in clinical practice, and how do you decide if a patient with hormone-receptor positive breast cancer is suited for endocrine monotherapy, targeted combination therapy or chemotherapy?
Q2. How can this decision-making process be made less subjective in the future?
Support: This video was supported by AstraZeneca.
